BioNxt Solutions Inc. (CVE:BNXT) | WebDisclosure

Basculer en Français

10812	Companies
234220	Keywords
162997	Articles
125217	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

BRIEF

published on 08/04/2026 at 09:10, 3 days 9 hours ago

BioNxt Solutions fait le point sur les progrès réalisés en matière d'administration sublinguale de médicaments.

Propriété Intellectuelle Innovation Pharmaceutique Administration Sublinguale De Médicaments Développement De La Cladribine Évérolimus Et Sémaglutide
BRIEF

published on 08/04/2026 at 09:10, 3 days 9 hours ago

BioNxt Solutions Updates on Sublingual Drug Delivery Progress

Intellectual Property Pharmaceutical Innovation Sublingual Drug Delivery Cladribine Development Everolimus And Semaglutide
PRESS RELEASE

published on 08/04/2026 at 09:05, 3 days 9 hours ago

BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
BioNxt Solutions Inc. provides update on proprietary drug delivery pipeline focusing on Cladribine for MS, autoimmune diseases, Everolimus, Semaglutide. Strengthening IP portfolio

BioNxt Solutions Inc. Intellectual Property Autoimmune Diseases Cladribine Drug Delivery Pipeline
BRIEF

published on 08/01/2026 at 00:30, 6 days 18 hours ago

BioNxt Solutions Issues New Stock Options

Stock Options Canadian Securities Exchange Vesting BioNxt Solutions Option Plan
BRIEF

published on 08/01/2026 at 00:30, 6 days 18 hours ago

BioNxt Solutions émet de nouvelles options d'achat d'actions

Acquisition Options D'achat D'actions Solutions BioNxt Plan D'options Bourse Canadienne Des Valeurs Mobilières
PRESS RELEASE

published on 08/01/2026 at 00:25, 6 days 18 hours ago

BioNxt Solutions Announces Option Grants
BioNxt Solutions Inc. announces stock options grants under Option Plan to insiders, consultants, and employees. Focus on drug delivery innovations and cancer treatment platforms

Stock Options Cancer Treatment Innovations BioNxt Solutions Inc. Drug Delivery
BRIEF

published on 07/06/2026 at 09:10, 1 month 1 day ago

BioNxt Progresses with Sublingual Semaglutide ODF Development

Drug Delivery Pharmaceutical Development BioNxt Solutions Sublingual ODF GLP-1 Therapeutics
BRIEF

published on 07/06/2026 at 09:10, 1 month 1 day ago

BioNxt progresse dans le développement de l'ODF sublinguale de sémaglutide.

Développement Pharmaceutique Solutions BioNxt Administration De Médicaments ODF Sublingual Thérapeutiques GLP-1
PRESS RELEASE

published on 07/06/2026 at 09:05, 1 month 1 day ago

BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway
BioNxt Solutions Inc. announces progress in Semaglutide oral dissolvable film program for GLP-1 therapies, expanding into a rapidly growing pharmaceutical market

BioNxt Solutions Inc. Pharmaceutical Market Oral Dissolvable Film GLP-1 Therapies Semaglutide
BRIEF

published on 06/23/2026 at 23:25, 1 month 13 days ago

BioNxt Solutions Completes $2M Non-brokered Private Placement

Private Placement Securities Warrants Investments BioNxt Solutions

Accesswire

Published on 08/07/2026 at 14:17, 4 hours 17 minutes ago

NuRAN Wireless Increases Series A Preferred Share Financing to C$7.6 Million and Announces Debt Settlements
Published on 08/07/2026 at 13:00, 5 hours 34 minutes ago

Gold Terra Announces Start of Drilling on the Campbell Shear Northern Zone 103N Extension to Expand 2026 MRE of Inferred 595,000 Ounces, Con Mine, Yellowknife, NWT
Published on 08/07/2026 at 00:45, 17 hours 49 minutes ago

NXT Energy Solutions Announces Second Quarter 2026 Results
Published on 08/06/2026 at 23:15, 19 hours 19 minutes ago

LNG Energy Group Announces Issuance of Second Partial Revocation Order and Further Details on Private Placement Financing
Published on 08/06/2026 at 22:15, 20 hours 19 minutes ago

Biomind Labs Announces Listing on the Canadian Securities Exchange and the Delisting From the Cboe Canada

View all ACCESSWIRE

EQS Group

Published on 08/07/2026 at 18:10, 24 minutes ago

Stabilus SE: Andreas Jaeger steps down as Chief Financial Officer at his own request
Published on 08/07/2026 at 18:00, 34 minutes ago

E-PANGO: Composition du capital au 31 juillet 2026
Published on 08/07/2026 at 17:45, 49 minutes ago

Schroder ETFs ICAV: Publication of the Audited Annual Report for Switzerland
Published on 08/07/2026 at 17:34, 1 hour ago

Fuller, Smith & Turner PLC: Director/PDMR Shareholdings
Published on 08/07/2026 at 16:51, 1 hour 43 minutes ago

Issue of Equity

Les Echos

Published on 08/07/2026 at 18:00, 34 minutes ago

LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 juillet 2026
Published on 08/07/2026 at 17:49, 45 minutes ago

Crédit Agricole CIB annonce la publication de l’Amendement de son Document d’enregistrement universel 2025
Published on 08/07/2026 at 17:49, 45 minutes ago

Crédit Agricole CIB announced the publication of the Amendment of its 2025 Universal Registration Document
Published on 08/07/2026 at 17:35, 59 minutes ago

Production du 1ier semestre 2026
Published on 08/07/2026 at 15:36, 2 hours 58 minutes ago

NRJ Group - Information relative aux droits de vote au 31.07.2026 (French & English)

View all LES ECHOS COMFI WIRE